Alzamend Neuro Inc (ALZN)vsAstraZeneca PLC (AZN)
ALZN
Alzamend Neuro Inc
$1.21
-0.82%
HEALTHCARE · Cap: $6.27M
AZN
AstraZeneca PLC
$174.40
+7.02%
HEALTHCARE · Cap: $263.78B
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 62/100 (C+).
ALZN
Avoid28
out of 100
Grade: F
AZN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALZN.
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$174.40
$20.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALZN
The strongest argument for ALZN centers on Price/Book.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : ALZN
The primary concerns for ALZN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ALZN profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ALZN carries more volatility with a beta of 0.27 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 28/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alzamend Neuro Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alzamend Neuro Inc. is an innovative biotechnology company poised to revolutionize the treatment landscape for neurodegenerative diseases, especially Alzheimer's disease. Utilizing a proprietary drug development platform and a robust intellectual property portfolio, the company is strategically positioned to meet significant unmet medical needs in the pharmaceutical market. With a commitment to advancing its therapeutic candidates through rigorous clinical trials and fostering strategic partnerships, Alzamend Neuro aims to enhance patient quality of life and make substantial contributions to the neurotherapeutics sector. Its focused approach on critical neurological health challenges presents a compelling investment opportunity within the biotech industry.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?